AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30312378 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 4 (calculated expected absolute benefits)
Number of subjects: 0
Study 30312378 — intervention group
Group type: COMPARATOR
Intervention: Aggregate data methods
Number of subjects: 0
Study 30312378 — intervention group
Group type: COMPARATOR
Intervention: Gold-standard method (individual data from both the trial and CPRD)
Number of subjects: 0
Study 28246888 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (S)
Number of subjects: 20
Study 28246888 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (P)
Number of subjects: 20
Study 28246888 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 25690998 — intervention group
Group type: EXPERIMENTAL
Intervention: RVPAS group
Number of subjects: 275
Study 25690998 — intervention group
Group type: COMPARATOR
Intervention: Modified Blalock‐Taussig shunt group
Number of subjects: 275
Study 23269773 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty management intervention (scripted CD and guide booklet, supplemented by four scripted, 20-minute weekly training calls)
Number of subjects: 313
Study 23269773 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition (four scripted, 20-minute weekly training calls)
Number of subjects: 313
Study 21501482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem 3 days
Number of subjects: 142
Study 21501482 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-Sulbactam 3 days
Number of subjects: 142
Study 17919835 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy with or without concurrent chemotherapy
Number of subjects: 57
Study 16615971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 40 mug (CIC40)
Number of subjects: 1031
Study 16615971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 mug (CIC80)
Number of subjects: 1031
Study 16615971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 mug (CIC160)
Number of subjects: 1031
Study 16615971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1031
Study 12872086 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide insufflation
Number of subjects: 249
Study 12872086 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 249
Study 16570467 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intervention (EI) including cognitive behavioral skills training and biofeedback
Number of subjects: 0
Study 16570467 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention (NI)
Number of subjects: 0
Study 10230191 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone, 1.0 mg/kg, administered daily for 2 weeks
Number of subjects: 24
Study 10230191 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered daily for 2 weeks
Number of subjects: 24
Study 8752609 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant
Number of subjects: 20
Study 8752609 — intervention group
Group type: COMPARATOR
Intervention: Control (bilateral tubal ligation)
Number of subjects: 20
Study 1819154 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride
Number of subjects: 74
Study 1819154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 6411791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mixture of eight essential l-amino acids, hypertonic dextrose, and vitamins
Number of subjects: 0
Study 6411791 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic dextrose and vitamins alone
Number of subjects: 0
Study 27908668 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure near a steel mill
Number of subjects: 61
Study 27908668 — intervention group
Group type: COMPARATOR
Intervention: Exposure at a location five kilometres away from the steel mill
Number of subjects: 61
Study 26563497 — intervention group
Group type: EXPERIMENTAL
Intervention: Salidroside (Sal) 20 mg/kg
Number of subjects: 5
Study 26563497 — intervention group
Group type: EXPERIMENTAL
Intervention: Salidroside (Sal) 40 mg/kg
Number of subjects: 5
Study 26563497 — intervention group
Group type: EXPERIMENTAL
Intervention: Salidroside (Sal)
Number of subjects: 5
Study 26563497 — intervention group
Group type: EXPERIMENTAL
Intervention: RIP140/NF-κB signaling
Number of subjects: 5
Study 26563497 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (7.5 mg/kg)
Number of subjects: 5
Study 26563497 — intervention group
Group type: COMPARATOR
Intervention: Vehicle group
Number of subjects: 5
Study 26563497 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 5
Study 24737301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ajust
Number of subjects: 120
Study 24737301 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniArc
Number of subjects: 120
Study 24737301 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT Secur System
Number of subjects: 120
Study 23091157 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 with commercially available synbiotic Duolac, containing 500 cfu of both Lactobacillus acidophilus and Streptococcus faecium with the addition of lactose (0.001 mg/embryo)
Number of subjects: 60
Study 23091157 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 and T4 groups
Number of subjects: 60
Study 23091157 — intervention group
Group type: EXPERIMENTAL
Intervention: T1, T2, T3, T4 (treated groups)
Number of subjects: 60
Study 23091157 — intervention group
Group type: COMPARATOR
Intervention: C group (control with physiological saline)
Number of subjects: 60
Study 19085044 — intervention group
Group type: EXPERIMENTAL
Intervention: Schistosomal infection group
Number of subjects: 100
Study 19085044 — intervention group
Group type: COMPARATOR
Intervention: Control group (without schistosomal infection)
Number of subjects: 100
Study 17894913 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural diamorphine (5 mg)
Number of subjects: 60
Study 17894913 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular diamorphine (5 mg)
Number of subjects: 60
Study 14685103 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (recombinant human granulocyte colony-stimulating factor)
Number of subjects: 60
Study 14685103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12236325 — intervention group
Group type: EXPERIMENTAL
Intervention: High perceived control over aversive noise
Number of subjects: 32
Study 12236325 — intervention group
Group type: COMPARATOR
Intervention: Low perceived control over aversive noise
Number of subjects: 32
Study 9684386 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/day buprenorphine
Number of subjects: 736
Study 9684386 — intervention group
Group type: COMPARATOR
Intervention: 1 mg/day buprenorphine
Number of subjects: 736
Study 9684386 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/day buprenorphine
Number of subjects: 736
Study 9684386 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg/day buprenorphine
Number of subjects: 736
Study 8210019 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose epidural anaesthesia using 0.375% bupivacaine
Number of subjects: 50
Study 8210019 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 50
Study 2702250 — intervention group
Group type: EXPERIMENTAL
Intervention: Alipase (P) - 9 capsules/day
Number of subjects: 35
Study 2702250 — intervention group
Group type: COMPARATOR
Intervention: Eurobiol (E) - 3 vials/day
Number of subjects: 35
Study 31919090 — intervention group
Group type: EXPERIMENTAL
Intervention: ofatumumab-CHL (O-CHL)
Number of subjects: 383
Study 31919090 — intervention group
Group type: COMPARATOR
Intervention: chlorambucil (CHL)
Number of subjects: 383
Study 31888733 — intervention group
Group type: EXPERIMENTAL
Intervention: 22G Franseen needle
Number of subjects: 520
Study 31888733 — intervention group
Group type: COMPARATOR
Intervention: 22G conventional needle
Number of subjects: 520
Study 28728565 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab plus methotrexate
Number of subjects: 60
Study 28728565 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 60
Study 28728565 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 60
Study 28728565 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who did not achieve sDFR)
Number of subjects: 60
Study 24942481 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural therapy
Number of subjects: 0
Study 24942481 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 23773041 — intervention group
Group type: EXPERIMENTAL
Intervention: Distrust (untrustworthy interaction)
Number of subjects: 0
Study 23773041 — intervention group
Group type: EXPERIMENTAL
Intervention: Distrust (priming manipulation)
Number of subjects: 0
Study 23773041 — intervention group
Group type: EXPERIMENTAL
Intervention: Distrust
Number of subjects: 0
Study 23773041 — intervention group
Group type: EXPERIMENTAL
Intervention: Distrust (when dissimilarity-focus was impaired)
Number of subjects: 0
Study 23773041 — intervention group
Group type: COMPARATOR
Intervention: Trust (trustworthy interaction)
Number of subjects: 0
Study 23773041 — intervention group
Group type: COMPARATOR
Intervention: Trust-unrelated interaction
Number of subjects: 0
Study 21969870 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir
Number of subjects: 2413
Study 21969870 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group from the Vaccine Trial)
Number of subjects: 2413
Study 20434251 — intervention group
Group type: EXPERIMENTAL
Intervention: Welfare-to-work
Number of subjects: 8393
Study 20434251 — intervention group
Group type: COMPARATOR
Intervention: Traditional welfare benefits
Number of subjects: 8393
Study 18098357 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-axial injection technique (MAI technique)
Number of subjects: 103
Study 18098357 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection technique (CI technique)
Number of subjects: 103
Study 16270608 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) via propofol and remifentanil infusion
Number of subjects: 56
Study 16270608 — intervention group
Group type: COMPARATOR
Intervention: Inhaled sevoflurane with incremental doses of fentanyl
Number of subjects: 56
Study 12398959 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 325
Study 12398959 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 325
Study 12398959 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 325
Study 12398959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 9934892 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 18
Study 9934892 — intervention group
Group type: COMPARATOR
Intervention: 5% albumin
Number of subjects: 18
Study 7484777 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 42
Study 7484777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 2249378 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol (200 to 1600 mg/day)
Number of subjects: 292
Study 2249378 — intervention group
Group type: COMPARATOR
Intervention: atenolol (50 to 100 mg/day)
Number of subjects: 292
Study 7317247 — intervention group
Group type: EXPERIMENTAL
Intervention: Equipotent doses (UD95) of thiopentone
Number of subjects: 48
Study 7317247 — intervention group
Group type: EXPERIMENTAL
Intervention: Equipotent doses (UD95) of Althesin
Number of subjects: 48
Study 31202641 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg
Number of subjects: 68
Study 31202641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 27789807 — intervention group
Group type: EXPERIMENTAL
Intervention: N95 respirators (compliant and non-compliant)
Number of subjects: 1074
Study 27789807 — intervention group
Group type: COMPARATOR
Intervention: Non-compliant N95 wearers
Number of subjects: 1074
Study 25567775 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT) for 12 months, 2-3 sessions/week
Number of subjects: 42
Study 25567775 — intervention group
Group type: COMPARATOR
Intervention: Control group (inactive)
Number of subjects: 42
Study 25567775 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT)
Number of subjects: 42
Study 23981722 — intervention group
Group type: EXPERIMENTAL
Intervention: Black seed oil (40-80 mg/kg/day)
Number of subjects: 30
Study 23981722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20227261 — intervention group
Group type: COMPARATOR
Intervention: Control diet providing a 500kcal/day deficit, with 500‐600mg/day dietary calcium
Number of subjects: 100
Study 20227261 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-supplemented diet with 800mg/day of calcium as calcium carbonate
Number of subjects: 100
Study 20227261 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk diet providing a 500kcal/day deficit and containing three servings of low‐fat milk
Number of subjects: 100
Study 20227261 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy milk diet providing a 500kcal/day deficit and containing three servings of calcium fortified soy milk
Number of subjects: 100
Study 19248543 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized Prolate Ablation (OPA)
Number of subjects: 14
Study 19248543 — intervention group
Group type: COMPARATOR
Intervention: Conventional Ablation (Control)
Number of subjects: 14
Study 17224000 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 120
Study 17224000 — intervention group
Group type: COMPARATOR
Intervention: metformin
Number of subjects: 120
Study 14725704 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystotomy with capitonnage (Group A, n = 32 patients, n = 38 cysts)
Number of subjects: 59
Study 14725704 — intervention group
Group type: COMPARATOR
Intervention: Cystotomy without capitonnage (Group B, n = 27 patients, n = 32 cysts)
Number of subjects: 59
Study 12575606 — intervention group
Group type: EXPERIMENTAL
Intervention: Sini Decoction (SND) treatment
Number of subjects: 22
Study 12575606 — intervention group
Group type: COMPARATOR
Intervention: Control (no SND treatment)
Number of subjects: 22
Study 9398810 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily
Number of subjects: 8
Study 9398810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8201388 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (FAC: fluorouracil, doxorubicin, and cyclophosphamide)
Number of subjects: 2624
Study 8201388 — intervention group
Group type: COMPARATOR
Intervention: Observation (surgery alone)
Number of subjects: 2624
Study 8201388 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (FAC)
Number of subjects: 2624
Study 8201388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy
Number of subjects: 2624
Study 3365530 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose indomethacin (50 mg/day) combined with paracetamol (4 g/day)
Number of subjects: 17
Study 3365530 — intervention group
Group type: COMPARATOR
Intervention: High-dose indomethacin (150 mg/day)
Number of subjects: 17
Study 30358019 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus (PR-T)
Number of subjects: 33
Study 30358019 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release tacrolimus (IR-T)
Number of subjects: 33
Study 27274772 — intervention group
Group type: EXPERIMENTAL
Intervention: US participants
Number of subjects: 0
Study 27274772 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with prior CVD
Number of subjects: 0
Study 27274772 — intervention group
Group type: COMPARATOR
Intervention: European participants
Number of subjects: 0
Study 24775991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ghrelin 3 mcg/kg
Number of subjects: 45
Study 24775991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ghrelin 1 mcg/kg
Number of subjects: 45
Study 24775991 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mcg/kg)
Number of subjects: 45
Study 22726581 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy with concomitant cisplatin
Number of subjects: 213
Study 22726581 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated radiotherapy without concomitant cisplatin
Number of subjects: 213
Study 22726581 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced N-classification
Number of subjects: 213
Study 22726581 — intervention group
Group type: EXPERIMENTAL
Intervention: Technically unresectable disease
Number of subjects: 213
Study 22726581 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss ratio
Number of subjects: 213
Study 22726581 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive measures
Number of subjects: 213
Study 22726581 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe acute dysphagia
Number of subjects: 213
Study 20385998 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon Alfa-2b (PEG-IFN)
Number of subjects: 220
Study 20385998 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 220
Study 18284597 — intervention group
Group type: EXPERIMENTAL
Intervention: RB006 (0.75 mg kg(‐1) intravenous bolus) followed by RB007 (2:1 to 0.125:1 antidote/drug ratio, 1.5 mg kg(‐1) to 0.094 mg kg(‐1))
Number of subjects: 39
Study 18284597 — intervention group
Group type: EXPERIMENTAL
Intervention: RB007 (antidote)
Number of subjects: 39
Study 18284597 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 39
Study 15868120 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 25620
Study 15868120 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 25620
Study 15868120 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Telmisartan and Ramipril
Number of subjects: 25620
Study 15868120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25620
Study 11837528 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech and language therapy for aphasia following stroke
Number of subjects: 0
Study 11837528 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews in rehabilitation
Number of subjects: 0
Study 9522243 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical isotretinoin gel 0.05%
Number of subjects: 30
Study 9522243 — intervention group
Group type: COMPARATOR
Intervention: Topical retinoic acid cream 0.05%
Number of subjects: 30
Study 7643294 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised version of SPPA
Number of subjects: 11315
Study 7643294 — intervention group
Group type: COMPARATOR
Intervention: Original SPPA
Number of subjects: 11315
Study 2692983 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A Behavior Pattern (TABP) assessment using the MYTH teacher rating scale
Number of subjects: 0
Study 2692983 — intervention group
Group type: EXPERIMENTAL
Intervention: Competition subscale of TABP
Number of subjects: 0
Study 385402 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml of betamethasone dipropionate + betamethasone phosphate (Diprospan)
Number of subjects: 42
Study 385402 — intervention group
Group type: COMPARATOR
Intervention: 2 ml of methylprednisolone acetate (Depomedrol)
Number of subjects: 42
Study 30852786 — intervention group
Group type: EXPERIMENTAL
Intervention: Question Prompt Sheet (QPS)
Number of subjects: 324
Study 30852786 — intervention group
Group type: COMPARATOR
Intervention: Question Listing (QL)
Number of subjects: 324
Study 29099399 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive distal pancreatectomy (MIDP)
Number of subjects: 1212
Study 28594150 — intervention group
Group type: COMPARATOR
Intervention: Cortical thickness analysis using the Freesurfer DK atlas and DS atlas
Number of subjects: 222
Study 28594150 — intervention group
Group type: COMPARATOR
Intervention: Surface-based morphometry (SBM)
Number of subjects: 222
Study 26444128 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic balloon catheters
Number of subjects: 27
Study 26444128 — intervention group
Group type: COMPARATOR
Intervention: Control group (no balloon catheters)
Number of subjects: 27
Study 23494328 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune No. 2 plus HAART
Number of subjects: 233
Study 21875604 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal drink
Number of subjects: 39
Study 21875604 — intervention group
Group type: COMPARATOR
Intervention: Control drink (water)
Number of subjects: 39
Study 21875604 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose drink
Number of subjects: 39
Study 19453049 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with midazolam 0.1 mg/kg, propofol 1 mg/kg, and fentanyl 1 microg/kg intravenously
Number of subjects: 90
Study 19453049 — intervention group
Group type: COMPARATOR
Intervention: Saline as a placebo
Number of subjects: 90
Study 16442399 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g of soy stanols
Number of subjects: 26
Study 16442399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 14586625 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO therapy (Hyperbaric oxygen) added to steroids, plasma expander dextrans, diazepam, pentoxiphylline and salt restriction
Number of subjects: 51
Study 14586625 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (steroids, plasma expander dextrans, diazepam, pentoxiphylline and salt restriction)
Number of subjects: 51
Study 11195740 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiron Technolas 217‐C excimer laser
Number of subjects: 28
Study 9621828 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately fluent processing
Number of subjects: 0
Study 9621828 — intervention group
Group type: COMPARATOR
Intervention: Highly fluent processing
Number of subjects: 0
Study 8158762 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular artery bypass surgery
Number of subjects: 111
Study 8158762 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile artery segments
Number of subjects: 111
Study 8158762 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior epigastric artery segments
Number of subjects: 111
Study 8158762 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dorsal vein segments
Number of subjects: 111